Identification of early stage recurrence endometrial cancer biomarkers using bioinformatics tools
Besso, María josé (Instituto de Biología y Medicina Experimental (Buenos Aires, Argentina))
Montivero, Luciana (Instituto de Biología y Medicina Experimental (Buenos Aires, Argentina))
Lacunza, Ezequiel (Centro de Investigaciones Inmunológicas, Básicas y Aplicadas, Facultad de Ciencias Médicas, Universidad Nacional de La Plata)
Argibay, María cecilia (Instituto de Biología y Medicina Experimental (Buenos Aires, Argentina))
Abba, Martín (Centro de Investigaciones Inmunológicas, Básicas y Aplicadas, Facultad de Ciencias Médicas, Universidad Nacional de La Plata)
Furlong, Laura I (Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut)
Colás Ortega, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Gil-Moreno, Antonio 1965- (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Reventos, Jaume (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Bello, Ricardo (Departamento de Metodología, Estadística y Matemática, Universidad de Tres de Febrero)
Vazquez-Levin, Mónica Hebe (Instituto de Biología y Medicina Experimental (Buenos Aires, Argentina))
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Endometrial cancer (EC) is the sixth most common cancer in women worldwide. Early diagnosis is critical in recurrent EC management. The present study aimed to identify biomarkers of EC early recurrence using a workflow that combined text and data mining databases (DisGeNET, Gene Expression Omnibus), a prioritization algorithm to select a set of putative candidates (ToppGene), protein-protein interaction network analyses (Search Tool for the Retrieval of Interacting Genes, cytoHubba), association analysis of selected genes with clinicopathological parameters, and survival analysis (Kaplan-Meier and Cox proportional hazard ratio analyses) using a The Cancer Genome Atlas cohort. A total of 10 genes were identified, among which the targeting protein for Xklp2 (TPX2) was the most promising independent prognostic biomarker in stage I EC. TPX2 expression (mRNA and protein) was higher (P<0. 0001 and P<0. 001, respectively) in ETS variant transcription factor 5-overexpressing Hec1a and Ishikawa cells, a previously reported cell model of aggressive stage I EC. In EC biopsies, TPX2 mRNA expression levels were higher (P<0. 05) in high grade tumors (grade 3) compared with grade 1-2 tumors (P<0. 05), in tumors with deep myometrial invasion (>50% compared with <50%; P<0. 01), and in intermediate-high recurrence risk tumors compared with low-risk tumors (P<0. 05). Further validation studies in larger and independent EC cohorts will contribute to confirm the prognostic value of TPX2.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Endometrial cancer ; Bioinformatics ; Biomarkers ; Recurrence ; TPX2
Publicat a:	Oncology Reports, Vol. 44 (june 2020) , p. 873-886, ISSN 1791-2431

DOI: 10.3892/or.2020.7648
PMID: 32705231

14 p, 1.3 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats